MARKET

RMD

RMD

Resmed
NYSE
183.42
-0.36
-0.20%
After Hours: 199.35 +15.93 +8.69% 19:38 04/25 EDT
OPEN
183.07
PREV CLOSE
183.78
HIGH
184.30
LOW
179.00
VOLUME
1.12M
TURNOVER
0
52 WEEK HIGH
243.52
52 WEEK LOW
131.49
MARKET CAP
26.98B
P/E (TTM)
30.39
1D
5D
1M
3M
1Y
5Y
BUZZ-ASX-listed shares of ResMed jump on strong quarterly results
ASX-listed shares of ResMed jump as much as 9.9% to A$31.58 on strong quarterly results. Medical device co beats Wall Street estimate for quarterly profit due to robust demand for sleep apnea devices. Shares set to see their best day since Oct 30, 2020.
Reuters · 9h ago
Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics
NASDAQ · 11h ago
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices. California-based company reported adjusted profit of $2.13 per share for the quarter ended March 31. Sales rose 7% to $1.2 billion. Shares of ResMed rose 9% in extended trading.
Reuters · 12h ago
Resmed Inc Q3 Profit Increases, beats estimates
NASDAQ · 13h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. Fresh2 Group stock rose 10.61% and ResMed stock rose 6.85% in the same session. The company's Q3 earnings came out today.
Benzinga · 13h ago
*ResMed 3Q R&D Expenses $226.7M >RMD
Dow Jones · 14h ago
Press Release: ResMed Inc. Announces Results for -3-
For the three and nine months ended March 31, 2017, we generated $ 300,492 in cash and cash equivalents. We generated $ 728,715 in net income and $ 667,892 in cash for the three months ending March 31. We expect to generate $1.2 billion in cash in the second quarter of 2018 and $2.1 billion in the third quarter. The Company's net income for the first three months of the year was $300,492.
Dow Jones · 14h ago
Press Release: ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024. Year-over-year revenue grows 7%, operating profit up 25%, and operating cash flows of $402 million. A webcast of ResMed's conference call will be available at 4:30 p.m. ET. Third Quarter 2024 revenue increased 7% to $1.2 billion.
Dow Jones · 14h ago
More
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.

Webull offers Resmed Inc stock information, including NYSE: RMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RMD stock methods without spending real money on the virtual paper trading platform.